Skip to main content
Premium Trial:

Request an Annual Quote

NIH Wants Optogenetics Studies of Neural Aging, Alzheimer's

NEW YORK (GenomeWeb News) – The National Institute on Aging plans to award up to $1 million next year to fund researchers who will explore the use of new optogenetic tools to study neural systems and their function, as well as to investigate Alzheimer's disease.

Optogenetics techniques, which use light to affect and control the activities of individual cells in living organisms, could help researchers studying aging-related disorders overcome a major impediment to their studies, the institute said in a request for applications Friday.

Recent research has uncovered aberrant neural activities that occur in the course of aging, but so far it has been difficult to study whether these activities cause disorders as there is a lack of tools for manipulating neural activity in living organisms in a controlled manner.

Optogenetic tools may offer a way for investigators to manipulate neural activities such that they may be studied and their effects may be observed.

NIA wants researchers to use this funding to develop optogenetic technologies for use in research into the normal and pathological aging of several neural systems, including sensory, motor, cognitive, emotional, autonomic, sleep, and neurovascular systems, and in Alzheimer's disease.

For studying neural systems, optogenetics technologies rely on using opsins – single-component microbial light activated regulators – that can activate neuronal firing by using light, or can inhibit neural activities in response to light, enabling researchers to elevate or suppress neural activity in living animal models, including rodents and non-human primates.

These technologies have yet to be used widely in aging and Alzheimer's research, according to NIA.

These three or four NIA awards will fund studies that combine optogenetics with other cellular, molecular, genetic, neuroimaging, and behavioral research methods.

Researchers may use the funding for wide a range of efforts to identify neural circuits, systems, and functioning and how they affect or are affected by aging and Alzheimer's disease.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.